Qiong Ye1,2,3, Guo-Ping Tian2, Hai-Peng Cheng1, Xin Zhang1, Xiang Ou4, Xiao-Hua Yu1, Ru-Qi Tan2, Feng-Yun Yang2, Duo Gong1, Chong Huang1, Yan-Jun Pan2, Jie Zhang5, Ling-Yan Chen1, Zhen-Wang Zhao1, Wei Xie1, Liang Li1, Min Zhang1, Xiao-Dan Xia1, Xi-Long Zheng6, Chao-Ke Tang1. 1. Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, Medical Research Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China. 2. Department of Cardiovascular Medicine, The Second Affiliated Hospital of University of South China. 3. Department of Ultrasound, Huadu District People's Hospital of Guangzhou. 4. Department of Endocrinology, The First Hospital of Changsha. 5. Department of Spinal Surgery, The Second Affiliated Hospital of University of South China. 6. Department of Biochemistry and Molecular Biology, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Health Sciences Center.
Abstract
AIMS: Atherosclerosis is the most common cause of cardiovascular disease, such as myocardial infarction and stroke. Previous study revealed that microRNA (miR)-134 promotes lipid accumulation and proinflammatory cytokine secretion through angiopoietin-like 4 (ANGPTL4)/lipid lipoprotein (LPL) signaling in THP-1 macrophages. METHODS: ApoE KO male mice on a C57BL/6 background were fed a high-fat/high-cholesterol Western diet, from 8 to 16 weeks of age. Mice were divided into four groups, and received a tail vein injection of miR-134 agomir, miR-134 antagomir, or one of the corresponding controls, respectively, once every 2 weeks after starting the Western diet. After 8 weeks we measured aortic atherosclerosis, LPL Activity, mRNA and protein levels of ANGPTL4 and LPL, LPL/ low-density lipoprotein receptor related protein 1 Complex Formation, proinflammatory cytokine secretion and lipid levels. RESULTS: Despite this finding, the influence of miR-134 on atherosclerosis in vivo remains to be determined. Using the well-characterized mouse atherosclerosis model of apolipoprotein E knockout, we found that systemic delivery of miR-134 agomir markedly enhanced the atherosclerotic lesion size, together with a significant increase in proinflammatory cytokine secretion and peritoneal macrophages lipid contents. Moreover, overexpression of miR-134 decreased ANGPTL4 expression but increased LPL expression and activity in both aortic tissues and peritoneal macrophages, which was accompanied by increased formation of LPL/low-density lipoprotein receptor-related protein 1 complexes in peritoneal macrophages. However, an opposite effect was observed in response to miR-134 antagomir. CONCLUSIONS: These findings suggest that miR-134 accelerates atherogenesis by promoting lipid accumulation and proinflammatory cytokine secretion via the ANGPTL4/LPL pathway. Therefore, targeting miR-134 may offer a promising strategy for the prevention and treatment of atherosclerotic cardiovascular disease.
AIMS: Atherosclerosis is the most common cause of cardiovascular disease, such as myocardial infarction and stroke. Previous study revealed that microRNA (miR)-134 promotes lipid accumulation and proinflammatory cytokine secretion through angiopoietin-like 4 (ANGPTL4)/lipid lipoprotein (LPL) signaling in THP-1 macrophages. METHODS:ApoE KO male mice on a C57BL/6 background were fed a high-fat/high-cholesterol Western diet, from 8 to 16 weeks of age. Mice were divided into four groups, and received a tail vein injection of miR-134 agomir, miR-134 antagomir, or one of the corresponding controls, respectively, once every 2 weeks after starting the Western diet. After 8 weeks we measured aortic atherosclerosis, LPL Activity, mRNA and protein levels of ANGPTL4 and LPL, LPL/ low-density lipoprotein receptor related protein 1 Complex Formation, proinflammatory cytokine secretion and lipid levels. RESULTS: Despite this finding, the influence of miR-134 on atherosclerosis in vivo remains to be determined. Using the well-characterized mouseatherosclerosis model of apolipoprotein E knockout, we found that systemic delivery of miR-134 agomir markedly enhanced the atherosclerotic lesion size, together with a significant increase in proinflammatory cytokine secretion and peritoneal macrophages lipid contents. Moreover, overexpression of miR-134 decreased ANGPTL4 expression but increased LPL expression and activity in both aortic tissues and peritoneal macrophages, which was accompanied by increased formation of LPL/low-density lipoprotein receptor-related protein 1 complexes in peritoneal macrophages. However, an opposite effect was observed in response to miR-134 antagomir. CONCLUSIONS: These findings suggest that miR-134 accelerates atherogenesis by promoting lipid accumulation and proinflammatory cytokine secretion via the ANGPTL4/LPL pathway. Therefore, targeting miR-134 may offer a promising strategy for the prevention and treatment of atherosclerotic cardiovascular disease.
Authors: Xiaoquan Rao; Jixin Zhong; Andrei Maiseyeu; Bhavani Gopalakrishnan; Frederick A Villamena; Lung-Chi Chen; Jack R Harkema; Qinghua Sun; Sanjay Rajagopalan Journal: Circ Res Date: 2014-09-03 Impact factor: 17.367
Authors: Werner J Geldenhuys; Joel Caporoso; Thomas C Leeper; Yoon-Kwang Lee; Li Lin; Altaf S Darvesh; Prabodh Sadana Journal: Bioorg Med Chem Lett Date: 2016-11-21 Impact factor: 2.823
Authors: Emilia Laudati; Andrew S Gilder; Michael S Lam; Roberta Misasi; Maurizio Sorice; Steven L Gonias; Elisabetta Mantuano Journal: Mol Cell Neurosci Date: 2016-08-23 Impact factor: 4.314
Authors: Wieneke Dijk; Anne P Beigneux; Mikael Larsson; André Bensadoun; Stephen G Young; Sander Kersten Journal: J Lipid Res Date: 2016-03-31 Impact factor: 5.922
Authors: Anna P Lillis; Selen Catania Muratoglu; Dianaly T Au; Mary Migliorini; Mi-Jeong Lee; Susan K Fried; Irina Mikhailenko; Dudley K Strickland Journal: PLoS One Date: 2016-01-21 Impact factor: 3.240